G. Halmos

发表

LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro

A. Schally, K. Groot, Z. Rékási, 1994, Peptides.

Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs

E. Rodríguez-Martín, A. Schally, K. Groot, 1999, Journal of Cancer Research and Clinical Oncology.

Peptide analogs in the therapy of prostate cancer

A. Schally, Z. Rékási, A. Nagy, 2000, The Prostate.

Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.

A. Schally, N. Block, G. Halmos, 2009, International journal of oncology.

Hypothalamic Releasing Hormones

A. Schally, G. Halmos, Nikoletta Dobos, 2020 .

Hypothalamic Hormones and Cancer

A. Schally, K. Szepesházi, A. Nagy, 2001, Frontiers in Neuroendocrinology.

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers

B. Szende, A. Schally, F. Hébert, 2000, British Journal of Cancer.

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.

A. Schally, F. Hébert, K. Groot, 2000, European journal of cancer.

The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells. Effect of (D-Trp6)LH-RH on tumor-bearing Syrian golden hamsters.

B. Szende, A. Schally, K. Szepesházi, 1994, Receptor.

Luteinizing hormone‐releasing hormone antagonist Cetrorelix (SB‐75) and bombesin antagonist RC‐3940‐II inhibit the growth of androgen‐independent PC‐3 prostate cancer in nude mice

A. Schally, K. Groot, K. Szepesházi, 1997, The Prostate.

Inhibition of PC‐3 human prostate cancers by analogs of growth hormone‐releasing hormone (GH‐RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity

A. Schally, M. Krupa, K. Groot, 2002, International journal of cancer.

Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

A. Schally, G. Halmos, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.

A. Schally, K. Groot, K. Szepesházi, 1994, Acta oncologica.

Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers

G. Mező, G. Csík, G. Halmos, 2019, International journal of molecular sciences.

Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.

A. Schally, K. Groot, K. Szepesházi, 1998, European journal of cancer.

Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma

A. Schally, Lóránt Székvölgyi, G. Méhes, 2020, Life.

Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel

C. Datz, A. Schally, K. Szepesházi, 2006, Proceedings of the National Academy of Sciences.

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations

A. Schally, J. Engel, Gunhild Keller, 2006, Proceedings of the National Academy of Sciences.

Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.

A. Schally, K. Groot, Gabor L. Toller, 2005, The Journal of clinical endocrinology and metabolism.

Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215

A. Schally, J. Engel, Gunhild Keller, 2005, Clinical Cancer Research.

Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.

A. Schally, J. Engel, Gunhild Keller, 2005, Fertility and sterility.

High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.

D. Bostwick, A. Schally, R. Davis, 2000, The Journal of clinical endocrinology and metabolism.

in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215

A. Schally, K. Groot, Baodong Sun, 2000, International journal of cancer.

Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.

A. Schally, F. Hébert, K. Groot, 2003, Cancer research.

Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162

A. Schally, K. Szepesházi, G. Halmos, 2009, Peptides.

Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches

A. Schally, B. Dezső, Z. Hernádi, 2022, Molecules.

Carcinoma the Proliferation of Experimental Non-Small Cell Lung Antagonists of Growth Hormone-Releasing Hormone Inhibit

A. Schally, F. Hébert, K. Groot, 2003 .

Complete regression of MX‐1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone–releasing hormone, AN‐207

A. Schally, K. Groot, J. M. Arencibia, 1999, Cancer.

Gene expression of vasoactive intestinal peptide receptors in human lung cancer.

A. Schally, G. Halmos, M. Szilasi, 2011, International journal of oncology.

Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma

A. Schally, G. Méhes, G. Halmos, 2018, Molecules.

Targeting to Peptide Receptors

A. Schally, G. Halmos, 2011 .

Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium.

A. Schally, A. Nagy, G. Halmos, 2003, Life Science.

Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.

A. Schally, F. Hébert, K. Szepesházi, 2002, Cancer research.

Independently of Their p 53 Status Somatostatin Receptor-positive Experimental Colon Cancers Targeted Cytotoxic Somatostatin Analogue AN-238 Inhibits Updated

A. Schally, F. Hébert, K. Szepesházi, 2002 .

Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.

A. Schally, K. Szepesházi, H. Kiaris, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells

C. Datz, S. Chandna, A. Schally, 2009, Cell cycle.

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice

A. Schally, K. Groot, J. M. Arencibia, 2000, Breast Cancer Research and Treatment.

Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II

A. Schally, K. Szepesházi, N. Block, 2012, Anti-cancer drugs.

LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.

A. Schally, K. Szepesházi, G. Halmos, 2007, International journal of oncology.

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.

A. Schally, K. Groot, K. Szepesházi, 1997, Journal of the National Cancer Institute.

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.

A. Schally, K. Groot, A. Jungwirth, 1997, British Journal of Cancer.

Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.

A. Schally, Baodong Sun, A. Nagy, 2002, International journal of oncology.

Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.

A. Schally, K. Groot, K. Szepesházi, 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.

A. Schally, K. Groot, G. Halmos, 1996, Endocrinology.

Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, Z. Rékási, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.

A. Schally, J. Wittliff, G. Halmos, 1995, Cancer research.

Inhibitory effect of bombesin/gastrin‐releasing peptide antagonist RC‐3095 and luteinizing hormone—releasing hormone antagonist SB‐75 on the growth of MCF‐7 MIII human breast cancer xenografts in athymic nude mice

A. Schally, K. Groot, K. Szepesházi, 1994, Cancer.

Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.

A. Schally, K. Groot, K. Szepesházi, 1994, British Journal of Cancer.

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

A. Schally, K. Groot, K. Szepesházi, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486.

A. Schally, J. Wittliff, G. Halmos, 1993, The Journal of clinical endocrinology and metabolism.

Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.

A. Schally, G. Halmos, J. Pinski, 1993, Cancer letters.

Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities

A. Schally, J. Hare, W. Sha, 2014, Peptides.

Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor

H. Koutselini, A. Schally, H. Kiaris, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Receptors for luteinizing hormone‐releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix

M. Nadji, A. Schally, N. Block, 2011, The Prostate.

Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas.

A. Schally, G. Halmos, J. Varga, 2006, International journal of oncology.

Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.

A. Schally, M. Krupa, Z. Rékási, 2002, The Journal of clinical endocrinology and metabolism.

Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix

A. Schally, G. Halmos, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.

A. Schally, Z. Rékási, T. Czompoly, 2000, Proceedings of the National Academy of Sciences of the United States of America.

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.

D. Bostwick, A. Schally, R. Davis, 2000, The Journal of urology.

Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.

A. Schally, A. Nagy, G. Halmos, 1999, Cancer letters.

Somatostatin receptor expression in lung cancer.

K. O'Byrne, A. Schally, K. Groot, 1994, European journal of cancer.

Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer.

A. Schally, B. Szoke, G. Halmos, 1994, Cancer letters.

Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.

A. Schally, Z. Rékási, T. Czompoly, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.

A. Schally, K. Groot, A. Jungwirth, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin–GnRH-III conjugates developed for targeted drug delivery

L. Buday, G. Mező, S. Schuster, 2018, Beilstein journal of organic chemistry.

Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth

A. Schally, W. Sha, N. Block, 2017, Peptides.

Efficient synthesis of an (aminooxy) acetylated‐somatostatin derivative using (aminooxy)acetic acid as a ‘carbonyl capture’ reagent

Ulrike Leurs, G. Mezö, Rózsa Hegedüs, 2011, Journal of peptide science : an official publication of the European Peptide Society.

New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs

A. Schally, K. Szepesházi, A. Nagy, 2004, Cellular and Molecular Life Sciences CMLS.

Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.

A. Schally, K. Groot, G. Halmos, 1996, Endocrinology.

Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action.

A. Schally, K. Groot, G. Halmos, 1996, Neuroendocrinology.

Synthesis and In Vitro Evaluation of New Potent Antagonists of Growth Hormone-Releasing Hormone (GH-RH)

A. Schally, K. Groot, Z. Kele, 1997, Peptides.

Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.

A. Schally, F. Hébert, K. Groot, 2001, Endocrinology.

Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia

M. Nadji, A. Schally, K. Szepesházi, 2011, Proceedings of the National Academy of Sciences.

Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs

S. Artavanis-Tsakonas, A. Schally, H. Kiaris, 2002, Proceedings of the National Academy of Sciences of the United States of America.

The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers

A. Schally, Baodong Sun, G. Halmos, 2000, Regulatory Peptides.

New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.

A. Schally, K. Groot, A. Nagy, 2009, The journal of peptide research : official journal of the American Peptide Society.

A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.

A. Schally, K. Groot, K. Szepesházi, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders

A. Schally, B. Dezső, G. Halmos, 2020, Molecules.

Somatostatin analog RC‐160 inhibits the growth of human osteosarcomas in nude mice

A. Schally, K. Groot, K. Szepesházi, 1996, International journal of cancer.

Inhibition of growth of MKN45 human gastric‐carcinoma xenografts in nude mice by treatment with bombesin/gastrin‐releasing‐peptide antagonist (RC‐3095) and somatostatin analogue RC‐160

A. Schally, K. Szepesházi, T. Yano, 1994, International journal of cancer.

Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice

A. Schally, K. Szepesházi, G. Halmos, 1993, International journal of cancer.

Novel antagonists of growth hormone‐releasing hormone inhibit growth and vascularization of human experimental ovarian cancers

A. Schally, A. Papadia, N. Block, 2012, Cancer.

Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.

A. Schally, F. Hébert, K. Szepesházi, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.

A. Schally, K. Groot, Gabor L. Toller, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.

A. Schally, K. Groot, V. Csernus, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors

A. Schally, K. Groot, K. Szepesházi, 2005, Breast Cancer Research and Treatment.

Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.

A. Bajo, A. Schally, F. Hébert, 2003, International journal of oncology.

Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma

A. Schally, G. Méhes, G. Halmos, 2017, Oncology reports.

Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition

A. Schally, K. Szepesházi, A. Papadia, 2009, Anti-cancer drugs.

A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.

A. Schally, F. Hébert, K. Szepesházi, 2001, European journal of cancer.

Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates

G. Mező, S. Schuster, I. Neundorf, 2022, International journal of molecular sciences.

Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.

A. Schally, K. Groot, Z. Rékási, 2000, Endocrinology.

Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.

A. Schally, F. Hébert, H. Kiaris, 2000, Cancer research.

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.

A. Schally, K. Szepesházi, A. Nagy, 1999, American journal of obstetrics and gynecology.

Targeted cytotoxic analog of luteinizing hormone‐releasing hormone AN‐207 inhibits the growth of PC‐82 human prostate cancer in nude mice

A. Schally, K. Groot, M. Koppán, 1999 .

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

A. Schally, K. Szepesházi, A. Nagy, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.

A. Schally, T. Ertl, G. Halmos, 1994, Cancer research.

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

A. Schally, K. Groot, K. Szepesházi, 1997, European journal of cancer.

Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.

A. Schally, K. Groot, K. Szepesházi, 1992, Journal of the National Cancer Institute.

Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.

A. Schally, K. Groot, K. Szepesházi, 1994, Cancer research.

LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia

A. Schally, N. Block, Jesus B. Fernandez, 2011, The Prostate.

Inhibition of the growth of caki‐I human renal adenocarcinoma in Vivo by luteinizing hormone‐releasing hormone antagonist cetrorelix, somatostatin analog RC‐160, and bombesin antagonist RC‐3940‐II

A. Schally, K. Groot, K. Szepesházi, 1998, Cancer.

Effect of bombesin, gastrin‐releasing peptide (GRP)(14–27) and bombesin/GRP receptor antagonist RC‐3095 on growth of nitrosamine‐induced pancreatic cancers in hamsters

A. Schally, K. Groot, K. Szepesházi, 1993, International journal of cancer.

Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238.

D. Pessayre, A. Schally, G. Feldmann, 2005, Journal of hepatology.

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy

Z. Karányi, Lóránt Székvölgyi, D. Páll, 2018, Front. Immunol..

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

A. Schally, Z. Rékási, G. Halmos, 2000, Breast Cancer Research and Treatment.

Inhibition of growth of MDA‐MB‐468 estrogen‐independent human breast carcinoma by bombesin/gastrin‐releasing peptide antagonists RC‐3095 and RC‐3940‐II

A. Schally, K. Groot, J. M. Arencibia, 2000, Cancer.

Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.

A. Schally, K. Szepesházi, G. Halmos, 2004, The Journal of urology.

Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.

A. Schally, K. Szepesházi, A. Nagy, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Incidence of unplanned oophorectomy at laparoscopic ovarian cystectomy for clinically benign cysts

A. Magos, G. Halmos, G. Papageorgiou, 2014, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors

A. Schally, Baodong Sun, A. Nagy, 2000 .

Human ovarian cancers express somatostatin receptors.

A. Schally, B. Sun, A. Nagy, 2000, The Journal of clinical endocrinology and metabolism.

Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone‐releasing hormone analog (AN‐152)

A. Schally, G. Vámosi, G. Halmos, 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A Rare Case of Asherman's Syndrome after Open Myomectomy: Sonographic Investigations and Possible Underlying Mechanisms

A. Magos, G. Halmos, D. Georgantzis, 2014, Gynecologic and Obstetric Investigation.

Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification

L. Buday, G. Mező, S. Schuster, 2018, Pharmaceutics.

Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.

É. Kiss, G. Mező, Rózsa Hegedüs, 2012, European journal of medicinal chemistry.

An audit of using the H Pipelle for endometrial sampling at outpatient hysteroscopy and literature review comparison with the Pipelle de Cornier.

A. Magos, G. Halmos, D. Georgantzis, 2012, European journal of obstetrics, gynecology, and reproductive biology.

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.

A. Schally, K. Groot, M. Vadillo-Buenfil, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.

A. Schally, K. Groot, A. Jungwirth, 1996, Endocrinology.

Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy.

J. Roszik, Z. Karányi, Beáta Boros-Oláh, 2019, DNA repair.

Investigational strategies for detection and intervention in early-stage pancreatic cancer

I. Zagon, S. Hubchak, M. Korc, 1994, International journal of pancreatology : official journal of the International Association of Pancreatology.

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC‐3 and DU‐145 human androgen‐independent prostate cancers

A. Schally, K. Groot, G. Halmos, 2005, The Prostate.

Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel

A. Schally, J. Engel, G. Halmos, 2007, Proceedings of the National Academy of Sciences.

The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.

K. Kovitz, A. Schally, K. Groot, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, Gabor L. Toller, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers

A. Schally, M. Krupa, G. Halmos, 2002, Peptides.

Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone

A. Schally, K. Groot, G. Halmos, 2001, Anti-cancer drugs.

Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways

A. Schally, K. Groot, Z. Rékási, 2001, Peptides.

Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.

A. Schally, K. Groot, G. Halmos, 2001, The Journal of clinical endocrinology and metabolism.

Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH).

A. Schally, K. Groot, A. Jungwirth, 1996, International journal of oncology.

Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, K. Szepesházi, 1995, Journal of the National Cancer Institute.

Selected chapters of Biopharmacy Lecture notes

G. Halmos, 2011 .

Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma

A. Schally, G. Halmos, R. Cai, 2005, Anti-cancer drugs.

Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes

G. Mezey, A. Klekner, L. Bognár, 2014, Journal of Cancer Research and Clinical Oncology.

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)

A. Schally, K. Szepesházi, Gunhild Keller, 2012, Oncotarget.

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild‐type p53 and decrease in p21 and mutant p53 proteins

A. Schally, G. Halmos, M. Zarándi, 2012, The Prostate.

Novel Crizotinib–GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems

M. Csala, A. Csámpai, Csilla E. Németh, 2019, International journal of molecular sciences.

Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors

A. Schally, T. Ertl, B. Szoke, 1994, Journal of Cancer Research and Clinical Oncology.

Inhibition of Growth of Experimental Human and Hamster Pancreatic Cancers In Vivo by a Targeted Cytotoxic Bombesin Analog

A. Schally, K. Szepesházi, A. Nagy, 2005, Pancreas.

Combination treatment of nitrosamiee-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist

A. Schally, K. Groot, K. Szepesházi, 1994, International journal of pancreatology : official journal of the International Association of Pancreatology.

Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist

A. Schally, K. Szepesházi, A. Jayakumar, 2013, Proceedings of the National Academy of Sciences.

The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma

A. Schally, G. Halmos, G. Oláh, 2020, Oncotarget.

RNA-DNA hybrid (R-loop) immunoprecipitation mapping: an analytical workflow to evaluate inherent biases.

E. Rajnavölgyi, E. Nagy, Z. Karányi, 2017, Genome research.

Inhibition of growth of MX‐1, MCF‐7‐MIII and MDA‐MB‐231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN‐238

A. Schally, K. Groot, Baodong Sun, 1999, International journal of cancer.

Inhibition of the UCI‐107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN‐238

A. Schally, M. Koppán, J. M. Arencibia, 2001, Cancer.

Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.

A. Schally, J. Engel, Gunhild Keller, 2005, Endocrine-related cancer.

Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas

A. Bajo, A. Schally, K. Szepesházi, 2003, Cancer.

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer

A. Schally, B. Dezső, J. Gardi, 2021, Molecules.

Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.

A. Schally, J. Engel, Gunhild Keller, 2006, International journal of oncology.

Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.

A. Schally, J. Engel, Gunhild Keller, 2005, Cancer research.

Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.

C. Datz, A. Schally, A. Papadia, 2010, Cancer letters.

Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues

A. Schally, J. Engel, Gunhild Keller, 2005, Clinical Cancer Research.

Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt

C. Datz, A. Schally, G. Halmos, 2007, Proceedings of the National Academy of Sciences.

Inhibition of growth of experimental prostate cancer in rats by LH‐RH analogs linked to cytotoxic radicals

A. Schally, K. Groot, K. Szepesházi, 1993, The Prostate.

Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108

M. Nadji, A. Schally, K. Szepesházi, 2013, Oncotarget.

Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines

A. Schally, G. Halmos, D. Rózsa, 2018, OncoTargets and therapy.

Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.

A. Schally, M. Koppán, J. M. Arencibia, 1998, Cancer research.

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

A. Schally, K. Szepesházi, M. Koppán, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Potentiation of the inhibitory effect of growth hormone‐releasing hormone antagonists on PC‐3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

A. Schally, K. Groot, Z. Rékási, 2000, The Prostate.

The "Ruston Stretch": a simple way to get a large specimen out through a small hole.

A. Magos, G. Halmos, D. Georgantzis, 2012, Journal of minimally invasive gynecology.

Terminology for luteinizing hormone-releasing hormone antagonists.

A. Schally, G. Halmos, J. Pinski, 1995, Fertility and sterility.

Inhibitory effects of analogs of luteinizing hormone‐releasing hormone on the growth of the androgen‐independent dunning R‐3327‐AT‐1 rat prostate cancer

A. Schally, K. Groot, G. Halmos, 1994, International journal of cancer.

Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC.

G. Halmos, K. Gombos, T. Flasko, 2016, Urologic oncology.

Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.

A. Schally, K. Groot, J. Horváth, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.

A. Juhász, G. Srkalović, Z. Rékási, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Comparative analysis of silage maize hybrids based on agronomic traits and chemical quality.

G. Halmos, F. Rácz, Z. Hegyi, 2009 .

Presence of receptors for bombesin/gastrin‐releasing peptide and mRNA for three receptor subtypes in human prostate cancers

A. Schally, Baodong Sun, Gabor Halmos, 2000, The Prostate.

Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin

A. Schally, K. Szepesházi, G. Halmos, 2008, Anti-cancer drugs.

Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.

A. Schally, J. Engel, Gunhild Keller, 2005, European journal of cancer.

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.

A. Schally, K. Groot, M. Koppán, 1999, The Prostate.

Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity

A. Schally, M. Mirsaeidi, W. Sha, 2021, Peptides.

Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.

A. Schally, K. Groot, Z. Rékási, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.

A. Schally, K. Szepesházi, G. Halmos, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone.

A. Schally, Z. Rékási, B. Szoke, 1993, Receptor.

Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines.

A. Schally, G. Halmos, P. Armatis, 1998, International journal of oncology.

Comparative in vitro biological evaluation of daunorubicin containing GnRH‐I and GnRH‐II conjugates developed for tumor targeting

S. Bősze, G. Mező, I. Szabó, 2015, Journal of peptide science : an official publication of the European Peptide Society.

Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.

A. Schally, A. Jungwirth, G. Halmos, 1998, International journal of oncology.

Prostate Cancer in Rats at Nontoxic Doses Growth of Androgen-independent Dunning R-3327-AT1 Targeted Cytotoxic Analogue of Somatostatin AN-238 Inhibits Updated

Andrew, J. M. Arencibia, A. Nagy, 2006 .

Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.

A. Schally, K. Groot, H. Reile, 1994, Cancer research.

Antagonists of bombesin/gastrin‐releasing peptide as adjuncts to agonists of luteinizing hormone–releasing hormone in the treatment of experimental prostate cancer

A. Schally, K. Szepesházi, G. Halmos, 1993, Cancer.

Targeted therapy with a cytotoxic somatostatin analog, AN‐238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR‐1

A. Schally, J. Engel, Gunhild Keller, 2005, Cancer.

Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.

A. Schally, J. Engel, Gunhild Keller, 2005, European journal of cancer.

Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer

A. Schally, K. Groot, K. Szepesházi, 1994 .

Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 can overcome chemoresistance in experimental renal cell carcinomas

A. Schally, J. Engel, Gunhild Keller, 2005, Cancer.

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.

M Kovacs, A. Schally, K. Groot, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.

A. Schally, K. Groot, Gabor L. Toller, 2004, Proceedings of the National Academy of Sciences of the United States of America.

The Inhibitory Effect of a Novel Cytotoxic Somatostatin Analogue AN-162 on Experimental Glioblastoma

A. Schally, G. Halmos, É. Pozsgai, 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Growth inhibition of experimental non‐Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN‐238

A. Schally, J. Engel, Gunhild Keller, 2005, International journal of cancer.

Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.

A. Bajo, A. Schally, A. Nagy, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses

A. Schally, H. Kiaris, A. Nagy, 2001, Anti-Cancer Drugs.

Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.

A. Schally, K. Szepesházi, A V Schally, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.

A. Schally, K. Groot, K. Szepesházi, 1997, Anti-cancer drugs.

Vapreotide labeled with Tc-99m for imaging tumors.

M. Thakur, A. Schally, E. John, 1996, International journal of oncology.

Effect of drought on yield components of maize hybrids (Zea mays L)

Z. Nagy, G. Halmos, J. Bányai, 2013 .

Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin.

A. Schally, K. Groot, K. Szepesházi, 1997, International journal of oncology.

Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 inhibits growth of experimental human prostate cancers

R. Vessella, E. Corey, A. Schally, 2006, International journal of cancer.

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma

A. Schally, N. Block, B. Dezső, 2013, Oncotarget.

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215

A. Bajo, A. Schally, K. Groot, 2002, British Journal of Cancer.

Ultrasound Used for Diagnostic Imaging Facilitates Dendritic Branching of Developing Neurons in the Mouse Cortex

E. Berényi, Z. Mészár, P. Szucs, 2022, Frontiers in Neuroscience.

Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.

A. Schally, K. Groot, Gabor L. Toller, 2006, Proceedings of the National Academy of Sciences of the United States of America.

The Prostate 68 : 1763 ^ 1772 ( 2008 ) Dose-DependentGrowth Inhibition InVivoof PC-3 ProstateCancerWith aReduction in TumoralGrowth FactorsAfterTherapyWith GHRHAntagonistMZ-J-7-138

A. Schally, K. Groot, G. Halmos, 2008 .

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers

A. Schally, K. Groot, G. Halmos, 2005 .

Growth Hormone-Releasing Hormone Antagonists Inhibit Growth of Human Ovarian Cancer

A. Schally, A. Papadia, J. Lucci, 2011, Hormone and Metabolic Research.

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA‐PCa‐2b and LuCaP‐35 prostate cancers

A. Schally, K. Groot, A. Havt, 2007, The Prostate.

Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.

A. Schally, K. Groot, K. Szepesházi, 2003, Cancer research.

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

A. Schally, K. Groot, K. Szepesházi, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Evaluation of the therapeutic efficacy of 213Bi-labelled DOTA-conjugated alpha-melanocyte stimulating hormone peptide analogues in melanocortin-1 receptor positive preclinical melanoma model.

G. Nagy, I. Mándity, F. Bruchertseifer, 2023, International journal of pharmaceutics.

Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone‐releasing hormone analog AN‐207

A. Schally, K. Szepesházi, A. Nagy, 2006, The Prostate.

Abstract. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit growth of various human cancers including osteosarcomas and Ewing's sarcomas, xenografted into nude mice or cultured in vitro. The antiproliferative effect of GH-RH

A. Schally, G. Halmos, J. Varga, 2006 .

Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors

B. Dezső, G. Halmos, B. Zsebik, 2023, Journal of clinical medicine.

Bombesin/gastrin‐releasing peptide antagonists RC‐3095 and RC‐3940‐II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H‐69 small cell lung carcinoma

A. Schally, M. Koppán, J. M. Arencibia, 1998, Cancer.

Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin’s lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207

A. Schally, J. Engel, Gunhild Keller, 2005 .

Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues

A. Schally, J. Engel, Gunhild Keller, 2005, Clinical Cancer Research.

Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.

A. Schally, G. Halmos, M. Zarándi, 2005, Cancer letters.

Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia

M. Nadji, A. Schally, K. Szepesházi, 2011, Proceedings of the National Academy of Sciences.

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations

A. Schally, J. Engel, Gunhild Keller, 2006, Proceedings of the National Academy of Sciences.

Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.

A. Schally, K. Groot, H. Reile, 1994, Cancer research.

NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review

G. Mező, G. Trencsényi, G. Halmos, 2023, International journal of molecular sciences.

Somatostatin receptor expression in lung cancer.

K. Groot, K. Szepesházi, D. Carney, 1994, European journal of cancer.

Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines

A. Schally, G. Halmos, D. Rózsa, 2018, OncoTargets and therapy.

characterization of luteinizing hormone-releasing hormone receptor type i (lh-rh-i) as a potential molecular target in OcM-1 and OcM-3 human uveal melanoma cell lines

G. Halmos, Nikoletta Dobos, Z. Szabó, 2018 .

characterization of luteinizing hormone-releasing hormone receptor type i (lh-rh-i) as a potential molecular target in OcM-1 and OcM-3 human uveal melanoma cell lines

G. Halmos, Nikoletta Dobos, Z. Szabó, 2018 .